Successful treatment of persistent MRSA bacteremia using high-dose daptomycin combined with rifampicin.

Published on Jan 1, 2014in Internal Medicine1.005
· DOI :10.2169/INTERNALMEDICINE.53.2711
Hideharu Hagiya13
Estimated H-index: 13
(Okayama University),
Tomohiro Terasaka10
Estimated H-index: 10
(Okayama University)
+ 5 AuthorsFumio Otsuka35
Estimated H-index: 35
(Okayama University)
We herein report a case of persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia that was successfully treated with combination therapy consisting of high-dose daptomycin (DAP, 10 mg/kg) and rifampicin. The patient's condition was complicated with multiple infectious foci, including an iliopsoas abscess and epidural abscess, as well as discitis and spondylitis at the cervical, thoracic and lumbar levels. Monotherapy treatments with vancomycin, linezolid and usual-dose DAP were all ineffective. It has been shown that usual-dose DAP administration may result in the emergence of a resistant strain and treatment failure. We would like to emphasize the importance of high-dose DAP therapy for MRSA bacteremia, a condition with a potentially high mortality rate.
#1Marco Falcone (Policlinico Umberto I)H-Index: 37
#2Alessandro Russo (Policlinico Umberto I)H-Index: 29
Last. Manjunath P. Pai (Albany College of Pharmacy and Health Sciences)H-Index: 30
view all 5 authors...
Background. Higher daptomycin doses are advocated for select methicillin-resistant Staphylococcus aureus (MRSA)–related infections, but the probabilities of target attainment (PTA) and toxicity of these doses have not been characterized in critically ill patients. Methods. We evaluated the plasma pharmacokinetics (PK) and clinical outcomes of a cohort of critically ill patients treated with daptomycin 6–8 mg/kg/day for primarily Staphylococcus species–related infections. Daptomycin concentration...
90 CitationsSource
#1Sebastiaan J. van Hal (University of Western Sydney)H-Index: 26
#2Vance G. Fowler (Duke University)H-Index: 103
For more than 4 decades, vancomycin has been the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Recently, infections due to isolates with high but susceptible vancomycin minimum inhibitory concentrations have been associated with additional treatment failures and patient mortality. These poorer outcomes may in part be explained by the inability of attaining appropriate vancomycin levels in these patients. However, assumptions that these poor outcomes are ...
92 CitationsSource
#1Marco Falcone (Sapienza University of Rome)H-Index: 37
#2Alessandro Russo (Sapienza University of Rome)H-Index: 29
Last. Mario Venditti (Sapienza University of Rome)H-Index: 66
view all 9 authors...
Pharmacokinetic studies of daptomycin in septic patients indicate that pharmacokinetic parameters may be altered. The purpose of this clinical investigation is to determine the pharmacokinetics of daptomycin in a population of hospitalized patients with clinically significant gram-positive infections and receiving daptomycin. Daptomycin was measured using an isocratic HPLC technique. Thirty-five patients suffering from gram-positive severe infections and receiving daptomycin were included in the...
45 CitationsSource
#1Sebastian Van Hal (University of Western Sydney)H-Index: 15
#2Slade O. Jensen (University of Western Sydney)H-Index: 24
Last. Iain B Gosbell (University of Western Sydney)H-Index: 28
view all 6 authors...
Summary: Staphylococcus aureus bacteremia (SAB) is an important infection with an incidence rate ranging from 20 to 50 cases/100,000 population per year. Between 10% and 30% of these patients will die from SAB. Comparatively, this accounts for a greater number of deaths than for AIDS, tuberculosis, and viral hepatitis combined. Multiple factors influence outcomes for SAB patients. The most consistent predictor of mortality is age, with older patients being twice as likely to die. Except for the ...
471 CitationsSource
#1S. J. van Hal (University of Western Sydney)H-Index: 23
#2Thomas P. Lodise (Albany College of Pharmacy and Health Sciences)H-Index: 51
Last. David L. Paterson (UQ: University of Queensland)H-Index: 128
view all 3 authors...
Background. Emerging data suggest that vancomycin may be less effective against serious methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibitory concentration (MIC) values at the higher end of the susceptibility range. The purpose of this review is to examine the strength of these associations.
407 CitationsSource
#1Carol L. Moore (HFH: Henry Ford Hospital)H-Index: 6
#2Paola Osaki-KiyanH-Index: 3
Last. Marcus J. Zervos (WSU: Wayne State University)H-Index: 57
view all 6 authors...
Background. Reports have found a link between vancomycin treatment failure in methicillin-resistant Staphyloccocus aureus (MRSA) bloodstream infections (BSIs) and higher vancomycin minimum inhibitory concentrations (MICs), despite MICs being below the susceptibility breakpoint of 2 lg/mL. Consensus guidelines recommend considering use of alternative agents for infections involving a higher vancomycin MIC, despite few data to support this approach. Methods. This retrospective case-control study e...
165 CitationsSource
12 CitationsSource
#1Catherine Liu (UCSF: University of California, San Francisco)H-Index: 17
#2Arnold S. Bayer (UCLA: University of California, Los Angeles)H-Index: 96
Last. Henry F. Chambers (UCSF: University of California, San Francisco)H-Index: 85
view all 12 authors...
Abstract Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), ba...
2,765 CitationsSource
#1Sheng-Hsiang LinH-Index: 11
#2Wan-Hsiu LiaoH-Index: 3
Last. Po-Ren Hsueh (NTU: National Taiwan University)H-Index: 105
view all 8 authors...
Results: Persistent MRSA bacteraemia occurred in 227 patients. Decreasing trends in the incidence of MRSA bacteraemia (P,0.001) and persistent MRSA bacteraemia (P ¼0.031) were found. Elevated vancomycin MICs for subsequent MRSA isolates were found in 49 (24.6%) of 199 patients, especially those with infective endocarditis (41.9% versus 21.4%; P ¼0.027). Metastatic infection [odds ratio (OR) 5.23; 95% confidence interval (CI) 2.17‐ 12.59; P,0.001], congestive heart failure (OR 4.78; 95% CI 2.19‐1...
39 CitationsSource
#1Elizabeth A. Neuner (Cleveland Clinic)H-Index: 16
#2Ed Casabar (Barnes-Jewish Hospital)H-Index: 10
Last. Peggy S. McKinnon (Cubist Pharmaceuticals)H-Index: 2
view all 4 authors...
Abstract Methicillin-resistant Staphylococcus aureus bacteremia (MRSAB) often persists despite full susceptibility to vancomycin; therefore, associated factors were assessed. A retrospective cohort analysis of 222 patients with MRSAB treated with vancomycin was conducted; patients with persistent MRSAB (pMRSAB) were compared to those with nonpersistent bacteremia (NPB). Incidence of pMRSAB was 9%. More patients with vancomycin MIC=2 mg/L had pMRSAB (16%) compared to patients with vancomycin MIC ...
55 CitationsSource
Cited By5
#1Rahul KashyapH-Index: 26
#2Aditya ShahH-Index: 6
Last. Rishi JainH-Index: 5
view all 6 authors...
Treatments and limitations for methicillin-resistant Staphylococcus aureus: A review of current literature
2 CitationsSource
#1Yi-Chien Lee (FJU: Fu Jen Catholic University)H-Index: 1
#2Pao-Yu Chen (NTU: National Taiwan University)H-Index: 9
Last. Shan-Chwen Chang (NTU: National Taiwan University)H-Index: 80
view all 4 authors...
Daptomycin is an important drug used in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection. A high dose of daptomycin is indicated for an MRSA infection with a minimum inhibitory concentration (MIC) of 1 mg/L for daptomycin. Combination therapies with daptomycin and other antimicrobial agents, including fosfomycin, display in vitro synergism potentially. This study was conducted to investigate the in vitro synergistic effect of daptomycin-based combination therapy agai...
8 CitationsSource
#1Paul O. Lewis (Johnson City Medical Center)H-Index: 6
#2Emily L. Heil (UMB: University of Maryland, Baltimore)H-Index: 17
Last. David Cluck (ETSU: East Tennessee State University)H-Index: 7
view all 4 authors...
WHAT IS KNOWN AND OBJECTIVE: Treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia is a long-standing challenge to health care, often complicated by metastatic infections, treatment failure and mortality. When MRSA bacteraemia persists despite adequate initial treatment, current Infectious Diseases Society of America guidelines recommend evaluation and removal of possible sources of infection. In addition, a change in therapy may be considered. The objective of this review ...
24 CitationsSource
Anerkannte Behandlungsmethoden der Spondylodiszitis sind Ruhigstellung und systemische Antibiose. Allerdings ist die Datenlage fur spezifische und weiterfuhrende Behandlungsempfehlungen sehr heterogen. Ziel dieser Ubersichtsarbeit ist die Therapieoptimierung der Spondylodiszitis anhand einer behandlungspfadorientierten Schweregradeinteilung im Konsens mit aktuellen Empfehlungen. Vom 1. 10. 1998 bis zum 31. 12. 2013 erfolgte die Etablierung einer Schweregradeinteilung mit spezifischen Therapieopt...
#1Nancy SandovalH-Index: 1
#2Santiago GrauH-Index: 25
Last. Juan Pablo HorcajadaH-Index: 54
view all 6 authors...
ABSTRACT Aim: We reviewed the clinical use of daptomycin in daily practice. Materials & methods: Efficacy and safety were assessed in 175 consecutive patients given daptomycin for at least 72 h. Results: Daptomycin was given as rescue treatment in 50.9% of cases. Bloodstream infection (34.8%) and skin/soft-tissue infection (19.4%) were the most frequent. In 62.3% of patients, the dose of ≤ 6 mg/kg/day was administered. Staphylococcus spp. were isolated in 52.6% of cases (MRSA in 9.5%, CoNS in 34...
5 CitationsSource